On July 7, 2020, the White House communicated to the UN Secretary General that the United States would officially withdraw from the World Health Organization (WHO). Additionally, in September, the United States announced that it will not join a global effort led by the WHO to develop, manufacture and distribute a vaccine against the coronavirus[1]. As the foremost health agency in world, the WHO works tirelessly to solve our world’s most complex public health problems, including the current pandemic. ICCR issued the following statement in response.
The below letter was sent to the following pharmaceutical companies by ICCR members on April 1, 2020 AbbVie; Amgen; Biogen; Bristol-Myers Squibb; Gilead; GSK; Eli Lilly; Johnson & Johnson; Merck; Pfizer; Novartis; Roche; Sanofi; Vertex
ICCR members asked President Biden to support an emergency COVID-19 waiver of World Trade Organization (WTO) intellectual property rules, so that greater supplies of vaccines, treatments, and diagnostic tests can be produced in as many places as possible as quickly as possible.
Statement for the Record by ICCR before United States Committee on Finance hearing on “Drug Pricing in America: A Prescription for Change, Part II”
These Principles are an articulation of our positions on corporate responsibility regarding global health, along with our recommended best practices. We welcome affirmation of these principles and practices by all stakeholders.